CoChat

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.

Open access
Abdrabou Abouelmagd, Alaa, Abdelrehim, Amro Mamdouh, Bashir, Mohamed Nabih, Abdelsalam, Fares, Marey, Ahmed, Tanas, Yousef, Abuklish, Duha Milad, Belal, Mohamed Mohamed · 2025 · Baylor University Medical Center Proceedings

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 7 of the 18 sources its claims cite were checked for support.

Abstract

Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria. Retatrutide significantly reduced body weight and improved metabolic outcomes. No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24). Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of three RCTs (878 patients) found retatrutide significantly reduced body weight and metabolic parameters versus placebo in obesity, with gastrointestinal adverse events more common at higher doses. The authors conclude retatrutide is promising but larger, longer trials are needed.

Key findings

  • Pooled body weight reduction was MD −14.33% (95% CI −18.27 to −10.39, P < 0.00001) after 36 weeks; dose subgroups were 4 mg −9.86%, 8 mg −16.31%, and 12 mg −16.90%.
  • Significant reductions were also reported for BMI (MD −5.38), waist circumference (MD −10.51 cm), fasting plasma glucose (MD −23.51 mg/dL), HbA1c (MD −0.91%), systolic blood pressure (MD −9.88 mm Hg), and diastolic blood pressure (MD −3.88 mm Hg), all with P < 0.00001.
  • Odds ratios for achieving ≥5%, ≥10%, and ≥15% weight loss were 43.34, 89.84, and 46.93, respectively (all P < 0.00001).
  • Overall adverse events were not significantly different at 4 mg (RR 1.11, P = 0.24), but were increased at 8 mg (RR 1.23, P = 0.007) and 12 mg (RR 1.34, P < 0.0001); nausea, vomiting, decreased appetite, diarrhea, and constipation were higher with retatrutide.

Methods

  • Systematic review and meta-analysis following PRISMA and Cochrane Handbook standards; protocol registered in the Open Science Framework (10.17605/OSF.IO/EX2UD). PubMed, Scopus, Web of Science, and Cochrane were searched from inception until May 1, 2024.
  • Included randomized controlled trials comparing retatrutide with placebo in obese or overweight patients with or without type 2 diabetes; excluded healthy populations, non-English texts, single-arm studies, animal studies, and abstracts. Three RCTs with 878 patients (748 retatrutide, 130 placebo) were included.
  • RevMan 5.4 was used; continuous outcomes were pooled as mean differences and categorical outcomes as relative risks or odds ratios with 95% CIs. A random-effects model was used when I² > 60% or χ² P < 0.1; subgroup analysis was by dose (4 mg, 8 mg, 12 mg).

Limitations

  • The paper states high heterogeneity in some analyses, a small number of included RCTs, small sample sizes, and a lack of long-term data on sustainability of weight loss and safety.
  • The paper states that heterogeneity in most efficacy outcomes could not be resolved by leave-one-out or sensitivity analysis because only two studies were included in the efficacy analysis.
  • Evident from the text: included trials were phase 1b/2 with short treatment durations (12–48 weeks), mostly conducted in the USA, and no head-to-head trials with other antiobesity medications were included.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/08998280.2025.2456441

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.From the PDF
Figure 2 Risk of bias assessment.
Figure 2 Risk of bias assessment.From the PDF
Figure 3 Forest plot of the percent weight reduction in different retatrutide doses.
Figure 3 Forest plot of the percent weight reduction in different retatrutide doses.From the PDF

Verification

Claims the paper makes

4 Valid · 0 Not valid · 3 Not checked · 37 Own results and interpretations

24 more claims

Create a free account to see all 44 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. World Obes Fed. 2023;(March):5–25. www.johnclarksondesign.co.uk
  2. 10.1186/S13643-016-0384-4/FIGURES/6 · doi:10.1186/s13643-016-0384-4/figures/6

Cited by

See all 25

Metadata

Authors
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M.
Affiliations
  • Faculty of Medicine, South Valley University
  • Misr University for Science and Technology (EG)
  • Alexandria University (EG)
  • Al-Azhar University (EG)
  • Houston Methodist (US)
  • Tripoli Central Hospital (LY)
Corresponding author
Belal, Mohamed Mohamed
Venue
Baylor University Medical Center Proceedings
Published
2025-02-05
Volume
38
Issue
3
Pages
291-303
ISSN
  • 0899-8280 (ISSN-L)
  • 1525-3252
OpenAlex
W4407175317
Cited by
25
References
32
Citations by year
2026: 20 · 2025: 5
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • Baylor University Medical Center Proceedings (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight loss, glycemic control, blood pressure, diabetes mellitus, drug safety, dose comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1080/08998280.2025.2456441
The paper
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings. https://doi.org/10.1080/08998280.2025.2456441

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.